Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 3—March 2011
Dispatch

Molecular Epidemiology of Mycobacterium tuberculosis, Buenos Aires, Argentina

Ximena GonzaloComments to Author , Marta Ambroggi, Ezequiel Cordova, Tim Brown, Susana Poggi, and Francis Drobniewski
Author affiliations: Author affiliations: Hospital de Infecciosas Francisco Javier Muñiz, Buenos Aires, Argentina (X. Gonzalo, M. Ambroggi, E. Cordova, S. Poggi); Clinical Sciences Research Center, London, UK (T. Brown, F. Drobniewski)

Main Article

Appendix

Table. Drug susceptibility profiles for 57 patients with MDR TB, Buenos Aires, Argentina, June 1, 2006–April 30, 2007*

Patient no. INH Rif P E Str PAS Cs Pto Eto Cm Am Km Cip Ofx Lfx Mfx
1 R R S S R S S S
2 R R R R S
3 R R S S R S S
4 R R R R R S S R R
5 R R R R R S S
6 R R R R R R S S R S S
7 R R R R
8 R R R S R S S R
9 R R S R S S
10 R R R R R R
11 R R R R R S S
12 R R R R R S S
13 R R R R R S S
14 R R S R R S S
15 R R R R R S S S S R R R S S
16 R R R R R S S R R R S S
17 R R R R R S S R
18 R R R R R S S S R R R R S S
19 R R R R R S S S S R R R S S S
20 R R R S R S S S R R R S S
21 R R R R R S S R R R S S S
22 R R R R S S R
23 R R R R R R R R R R
24 R R R R R S R R R S S R S S
25 R R S R R S S S
26 R R R R R S S
27 R R R R R R S R R
28 R R R R R R S R S
29 R R R S S S
30 R R R S S S S S
31 R R S S R S S S
32 R R S S R S S S
33 R R R R S S S
34 R R S R S
35 R R R R S S S S S
36 R R S R S S S
37 R R S S S S
38 R R R S S S S S
39 R R R R R S S R R R
40 R R S R R S S S S S
41 R R R R S S S S
42 R R R R S S R
43 R R S S S S R S S S S S
44 R R R R R R S S
45 R R R R R S S R
46 R R R R R S S R
47 R R S S R S S
48 R R R S S S
49 R R S S R S S S
50 R R R R R R R S R R R S
51 R R S R S S
52 R R S S S S S
53 R R R S S S R R S S
54 R R R R R S S R
55 R R S S
56 R R S S S S S
57 R R S R R S S S

*MDR, multidrug resistant; TB, tuberculosis; INH, isoniazid; Rif, rifampicin; P, pyrazinamide; E, ethambutol; Str, streptomycin; PAS, p-aminosalicylic acid; Cs, cycloserine; Pto, proteonamide; Eto, ethionamide; Cm, capreomycin; Am, amikacin; Km, kanamycin; Cip, ciprofloxacin; Ofx, ofloxacin; Lfx, levofloxacin; Mfx, moxifloxacin; R, resistant; S, susceptible; –, drugs not tested for those strains.

Main Article

Page created: July 25, 2011
Page updated: July 25, 2011
Page reviewed: July 25, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external